Skip to main content
Premium Trial:

Request an Annual Quote

Hoping for (More Than) the Best

A story in the BBC reports on the expected shift in human embryonic stem cell research policy under the incoming Obama administration. Many scientists are hopeful that he will lift the restrictive 2001 ban on certain cell lines, while others hope to see an infusion of cash and increased policy to support true bench-to-bedside research. "The impact of eight years under the previous administration for stem cell research has really been devastating," says Tom Okarma, head of stem cell company Geron. "We want the new administration to do more than the merely political -- of reversing the prior administration's ban."

The Scan

Another Resignation

According to the Wall Street Journal, a third advisory panel member has resigned following the US Food and Drug Administration's approval of an Alzheimer's disease drug.

Novavax Finds Its Vaccine Effective

Reuters reports Novavax's SARS-CoV-2 vaccine is more than 90 percent effective in preventing COVID-19.

Can't Be Used

The US Food and Drug Administration says millions of vaccine doses made at an embattled manufacturing facility cannot be used, the New York Times reports.

PLOS Papers on Frozen Shoulder GWAS, Epstein-Barr Effects on Immune Cell Epigenetics, More

In PLOS this week: genome-wide association study of frozen shoulder, epigenetic patterns of Epstein-Barr-infected B lymphocyte cells, and more.